SEC Form 4 · accession 0001144204-18-049517
Protalix BioTherapeutics, Inc. · PLX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Moshe Manor
Officer — President & CEO · Director
Period of report
Sep 13, 2018
Accepted (ET)
Sep 14, 2018 · 4:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001006281
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F2,F1 | $0.56 | Sep 13, 2018 | A | 1,300,000 | A | — | Sep 13, 2028 | Common Stock | 1,300,000 | 1,300,000 | D |
Explanation of responses
- F1The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended.
- F2Does not include options to purchase 900,000 shares of common stock at an exercise price equal to $2.37 per share that expire on September 29, 2024.